Activity depends on the signaling endpoint. At 0.1 μM with 6 h pretreatment, HS-173 did not inhibit SDF1α-induced ERK1/2 phosphorylation or significantly inhibit ARF1 activation in DU145, PC3 and HEK293 cells. [2,3]
In human stem cell-derived cardiomyocytes, HS-173 produced concentration-dependent apoptotic signaling across a 0.03–1 μM test range. Apoptosis at 0.03 μM was labeled nonsignificant. This provides a cellular liability signal without establishing clinical cardiac risk. [4]
Akt/P70S6K phosphorylation in hepatic stellate cells
Cell-based study · HSC-T6 and LX-2 hepatic stellate cell lines [1]
HS-173 lowered Akt and P70S6K phosphorylation in both lines. These cellular readouts support pathway inhibition, without establishing direct PI3Kα enzyme potency or isoform selectivity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1, 1 and 5 μM (24 h); 1 and 5 μM in the 6 h comparison with LY294002
- Exposure duration
- 24 h (Figure 5A); 6 h (Figure 5B)
- Method
- Cell treatment followed by immunoblotting
- Vehicle
- DMSO stock; final vehicle concentration for Figure 5 is not specified
- Reported limits
- Figure 5-specific vehicle concentration is not stated.
Methods and source locations
Compound reported in the paper: HS-173
Reported experimental HS-173 material; no equivalence to an Adooq lot, salt conversion, or clinical efficacy is inferred.
Figure 5A–B and caption; Results: HS-173 suppresses PI3K/Akt signaling; Methods: Preparation of HS-173, Western blotting
p-Akt/Akt and p-P70S6K/P70S6K: Western blotting with total Akt, total P70S6K and β-actin controls — Figure 5A–B and caption; Results: HS-173 suppresses PI3K/Akt signaling; Methods: Preparation of HS-173, Western blotting
HS-173 comparison in SDF1α-induced ERK signaling
Cell-based study · DU145, PC3 and HEK293 cells [2]
HS-173 did not visibly inhibit SDF1α-induced ERK1/2 phosphorylation under the tested condition; PI3Kγ/δ inhibitor comparators reduced the response.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1 μM
- Exposure duration
- 6 h pretreatment; SDF1α challenge for 5 min
- Method
- Immunoblot assay
- Co-treatment
- SDF1α 200 ng/mL challenge; other inhibitors were separate comparator conditions
- Reported limits
- HS-173 vehicle and catalog/lot identifiers are not specified in the reviewed methods.
Methods and source locations
Compound reported in the paper: HS-173
Reported experimental HS-173 material; no equivalence to an Adooq lot, salt conversion, or clinical efficacy is inferred.
Figure 4A and caption; Results: pharmacological inhibition of Gβγ downstream effectors; Experimental procedures: Materials, ERK1/2 activation
SDF1α-induced ERK1/2 phosphorylation: Phospho-ERK1/2 immunoblot with total ERK1/2 controls — Figure 4A and caption; Results: pharmacological inhibition of Gβγ downstream effectors; Experimental procedures: Materials, ERK1/2 activation
HS-173 comparison in SDF1α-induced ARF1 activation
Cell-based study · DU145, PC3 and HEK293 cells [3]
HS-173 did not significantly inhibit SDF1α-induced ARF1 activation, whereas PI3Kγ-directed comparator inhibition reduced activation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1 μM
- Exposure duration
- 6 h pretreatment; SDF1α challenge for 5 min
- Method
- Cellular ARF1 activation assay
- Co-treatment
- SDF1α 200 ng/mL challenge; inhibitor comparators were separate conditions
- Reported limits
- HS-173 vehicle and catalog/lot identifiers are not specified in the reviewed methods.
Methods and source locations
Compound reported in the paper: HS-173
Reported experimental HS-173 material; no equivalence to an Adooq lot, salt conversion, or clinical efficacy is inferred.
Figure 5A–B and caption; Results: PI3Kγ mediates ARF1 activation; Experimental procedures: Materials, GST fusion protein pulldown assays
Active ARF1 relative to total ARF1: GST–VHS–GAT pulldown followed by ARF1 immunoblotting — Figure 5A–B and caption; Results: PI3Kγ mediates ARF1 activation; Experimental procedures: Materials, GST fusion protein pulldown assays
Apoptotic signaling in human stem cell-derived cardiomyocytes
Cell-based study · Cor.4U human stem cell-derived cardiomyocytes [4]
HS-173 increased caspase-3/7 activity in this cellular model. The lowest tested concentration was labeled nonsignificant. This does not establish clinical cardiac risk.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.03, 0.1, 0.3 and 1 μM
- Exposure duration
- Apoptosis monitored over 24 h
- Method
- Live-cell caspase-3/7 imaging
- Vehicle
- 0.1% v/v DMSO control
- Reported limits
- The linked raw-data workbook request returned HTML rather than an XLSX file. No clinical exposure threshold is established for HS-173.
Methods and source locations
Compound reported in the paper: HS-173
Reported experimental HS-173 material; no equivalence to an Adooq lot, salt conversion, or clinical efficacy is inferred.
Figure 2B and caption; Tables 1 and 3; Results: Apoptosis, Beating Rate and Base Impedance, ATP; Materials and Methods
Caspase-3/7 apoptosis signal: Live-cell caspase-3/7 imaging during 24 h — Figure 2B (HS-173 graph) and caption; Results: Apoptosis